help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, P.
Right arrow Articles by Rosenfeld, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, P.
Right arrow Articles by Rosenfeld, R. G.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 1 90-98
Copyright © 2002 by The Endocrine Society


Endocrine Care

Effects of Dose and Gender on the Growth and Growth Factor Response to GH in GH-Deficient Children: Implications for Efficacy and Safety

Pinchas Cohen, George M. Bright, Alan D. Rogol, Anne-Marie Kappelgaard and Ron G. Rosenfeld on behalf of the American Norditropin Clinical Trials Group

Department of Pediatrics (P.C.), University of California Los Angeles, Los Angeles, California 90095; Department of Pediatrics (A.D.R.), University of Virginia, Charlottesville, Virginia 22903; Department of Pediatrics (R.G.R.), Oregon Health & Sciences University, Portland, Oregon 97201; Novo Nordisk (G.M.B.), Princeton, New Jersey 08540; and Novo Nordisk (A.-M.K.), DK2830 Copenhagen, Denmark

Address all correspondence and requests for reprints to: Pinchas Cohen, M.D., Professor and Director of Research and Training, Division of Endocrinology, Department of Pediatrics, Mattel Children’s Hospital at University of California Los Angeles, 10833 Le Conte Avenue, MDCC 22-315, Los Angeles, California 90095-1752. E-mail: hassy{at}mednet.ucla.edu

We evaluated the dose-response effects of GH on the growth and growth factor levels of GH-deficient patients. One hundred eleven short (-3.0 ± 0.9 height SD score), prepubertal GH-deficient children were randomized to receive low- (L; 0.025 mg/kg per day), medium- (M; 0.05 mg/kg per day), or high- (H; 0.1 mg/kg per day) dose GH. One hundred four children completed the 2-yr study. At 2 yr, the three groups displayed increases in height SD scores of 1.4 ± 0.1 for L, 2.2 ± 0.1 for M, and 2.3 ± 0.1 for H (P < 0.001 relative to L, P = NS relative to M). The serum levels of IGF-I and IGF binding protein-3 during treatment also demonstrated dependency on the GH dose and were independently correlated with the increase in height SD scores attained. Bone age advancement, the occurrence of puberty, fasting glucose, and hemoglobin A1c did not change during therapy, but fasting insulin levels rose in a dose-dependent manner. Surprisingly, the GH dose-response curve for both auxological and biochemical parameters differed between prepubertal females (n = 33) and males (n = 71). Males had a linear GH dose response, whereas females had an apparent plateau of both linear growth and IGF-I SD score responses at 0.05 mg/kg per day. In this large, randomized, 2-yr study, we observed a dose-response effect of GH on growth and serum growth factor levels and a prepubertal gender difference in GH sensitivity. These results suggest that the efficacy and theoretical safety of GH therapy can be optimized by modulating the GH dose in a gender-specific manner, based on the growth response and serum growth factor levels.

This study was supported by a research grant from Novo Nordisk. P.C., R.G.R., and A.D.R. served as nonequity consultants for Novo Nordisk. This work was presented in part at the 82nd Annual Meeting of The Endocrine Society, Toronto, Canada, 2000.

Abbreviations: GHD, GH-deficient; H, high; HbA1c, hemoglobin A1c; IGFBP-3, IGF-binding protein 3; L, low; M, medium; rhGH, recombinant human GH.




This article has been cited by other articles:


Home page
JCOHome page
L. Diller, E. J. Chow, J. G. Gurney, M. M. Hudson, N. S. Kadin-Lottick, T. I. Kawashima, W. M. Leisenring, L. R. Meacham, A. C. Mertens, D. A. Mulrooney, et al.
Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings
J. Clin. Oncol., May 10, 2009; 27(14): 2339 - 2355.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Kristrom, A. S. Aronson, J. Dahlgren, J. Gustafsson, M. Halldin, S. A. Ivarsson, N.-O. Nilsson, J. Svensson, T. Tuvemo, and K. Albertsson-Wikland
Growth Hormone (GH) Dosing during Catch-Up Growth Guided by Individual Responsiveness Decreases Growth Response Variability in Prepubertal Children with GH Deficiency or Idiopathic Short Stature
J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 483 - 490.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Bakker, J. Frane, H. Anhalt, B. Lippe, and R. G. Rosenfeld
Height Velocity Targets from the National Cooperative Growth Study for First-Year Growth Hormone Responses in Short Children
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 352 - 357.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. F. Collett-Solberg, M. Misra, and on behalf of the Drug and Therapeutics Committee o
The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 10 - 18.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. G Rosenfeld
Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature
Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S27 - S31.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Cohen, A. D. Rogol, C. P. Howard, G. M. Bright, A.-M. Kappelgaard, R. G. Rosenfeld, and on behalf of the American Norditropin Study Group
Insulin Growth Factor-Based Dosing of Growth Hormone Therapy in Children: A Randomized, Controlled Study
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2480 - 2486.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
O. Ali, M. Shim, E. Fowler, M. Greenberg, D. Perkins, W. Oppenheim, and P. Cohen
Growth Hormone Therapy Improves Bone Mineral Density in Children with Cerebral Palsy: A Preliminary Pilot Study
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 932 - 937.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega
Prediction of Adult Height in Growth-Hormone-Treated Children with Growth Hormone Deficiency
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 925 - 931.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Bouhours-Nouet, F. Gatelais, F. Boux de Casson, S. Rouleau, and R. Coutant
The Insulin-Like Growth Factor-I Response to Growth Hormone Is Increased in Prepubertal Children with Obesity and Tall Stature
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 629 - 635.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Cohen
Problems with Reclassification of Insulin-Like Growth Factor I Production and Action Disorders
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4235 - 4236.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. O. Reiter, D. A. Price, P. Wilton, K. Albertsson-Wikland, and M. B. Ranke
Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2047 - 2054.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Quigley, A. M. Gill, B. J. Crowe, K. Robling, J. J. Chipman, S. R. Rose, J. L. Ross, F. G. Cassorla, A. M. Wolka, J. M. Wit, et al.
Safety of Growth Hormone Treatment in Pediatric Patients with Idiopathic Short Stature
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5188 - 5196.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H K Gleeson and S M Shalet
The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours
Endocr. Relat. Cancer, December 1, 2004; 11(4): 589 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal
Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. M. Brownstein, A. C. Mertens, P. A. Mitby, M. Stovall, J. Qin, G. Heller, L. L. Robison, and C. A. Sklar
Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4422 - 4427.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
W. Xu, A. Janss, and T. Moshang
Adult Height and Adult Sitting Height in Childhood Medulloblastoma Survivors
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4677 - 4681.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
P. Saenger
Growth hormone in growth hormone deficiency
BMJ, July 13, 2002; 325(7355): 58 - 59.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society